July 23 (Reuters) - Biopharmaceutical firm Telix Pharmaceuticals (TLX) said on Monday it has launched an offering of A$600 million ($397.5 million) of convertible notes due 2029, in a bid to fund key clinical development programs across its theranostics portfolio.
($1 = 1.5094 Australian dollars)
- Forums
- ASX - By Stock
- TLX
- News: TLX Australia's Telix Pharmaceuticals launches $397.5 mln convertible bonds offering
News: TLX Australia's Telix Pharmaceuticals launches $397.5 mln convertible bonds offering
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.08 |
Change
-0.105(0.55%) |
Mkt cap ! $6.383B |
Open | High | Low | Value | Volume |
$18.93 | $19.37 | $18.75 | $20.46M | 1.076M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3 | $19.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.08 | 1003 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 257 | 19.060 |
7 | 856 | 19.050 |
11 | 1420 | 19.040 |
8 | 805 | 19.030 |
6 | 771 | 19.020 |
Price($) | Vol. | No. |
---|---|---|
19.070 | 315 | 3 |
19.080 | 404 | 5 |
19.090 | 977 | 8 |
19.100 | 1195 | 8 |
19.110 | 935 | 9 |
Last trade - 12.58pm 26/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |